929,102 Shares in Maze Therapeutics, Inc. $MAZE Bought by Woodline Partners LP

Key Points

• Woodline Partners LP has invested $10.23 million in Maze Therapeutics, acquiring approximately 929,102 shares, representing 2.12% of the company.
• Maze Therapeutics reported earnings of ($0.77) per share for the last quarter, beating analysts' expectations by $0.02.
• Analyst ratings for Maze Therapeutics show a consensus of "Buy" with a price target averaging $26.33, reflecting optimistic outlook in the market.

Woodline Partners LP bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 929,102 shares of the company's stock, valued at approximately $10,229,000. Woodline Partners LP owned about 2.12% of Maze Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of MAZE. TRV GP IV LLC bought a new position in shares of Maze Therapeutics in the 1st quarter worth $66,874,000. Frazier Life Sciences Management L.P. purchased a new position in Maze Therapeutics in the first quarter worth $45,460,000. ARCH Venture Management LLC purchased a new position in Maze Therapeutics in the first quarter worth $45,362,000. Matrix Capital Management Company LP bought a new position in Maze Therapeutics in the first quarter valued at $27,373,000. Finally, Alphabet Inc. purchased a new stake in Maze Therapeutics during the first quarter valued at about $26,561,000.

Maze Therapeutics Trading Down 0.2%

NASDAQ:MAZE traded down $0.05 during midday trading on Monday, reaching $23.25. 556,508 shares of the stock traded hands, compared to its average volume of 262,701. The company has a fifty day moving average of $15.28 and a 200 day moving average of $12.28. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.02.

Analyst Ratings Changes

MAZE has been the topic of several recent research reports. Guggenheim increased their price objective on Maze Therapeutics from $19.00 to $34.00 and gave the company a "buy" rating in a research report on Monday. BTIG Research upped their target price on Maze Therapeutics from $30.00 to $37.00 and gave the stock a "buy" rating in a research note on Friday. HC Wainwright lifted their price target on shares of Maze Therapeutics from $34.00 to $50.00 and gave the stock a "buy" rating in a research note on Friday. Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Finally, Wedbush started coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat, Maze Therapeutics presently has an average rating of "Buy" and an average price target of $32.67.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.